CN105380830B - A kind of composition and its application with anti-acne trace and suppression acne systematic function - Google Patents
A kind of composition and its application with anti-acne trace and suppression acne systematic function Download PDFInfo
- Publication number
- CN105380830B CN105380830B CN201510873881.2A CN201510873881A CN105380830B CN 105380830 B CN105380830 B CN 105380830B CN 201510873881 A CN201510873881 A CN 201510873881A CN 105380830 B CN105380830 B CN 105380830B
- Authority
- CN
- China
- Prior art keywords
- acne
- component
- parts
- trace
- phase component
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000002874 Acne Vulgaris Diseases 0.000 title claims abstract description 97
- 206010000496 acne Diseases 0.000 title claims abstract description 97
- 230000003255 anti-acne Effects 0.000 title claims abstract description 64
- 239000000203 mixture Substances 0.000 title claims abstract description 40
- 230000001629 suppression Effects 0.000 title claims abstract description 34
- 230000009897 systematic effect Effects 0.000 title description 7
- VGEREEWJJVICBM-UHFFFAOYSA-N phloretin Chemical compound C1=CC(O)=CC=C1CCC(=O)C1=C(O)C=C(O)C=C1O VGEREEWJJVICBM-UHFFFAOYSA-N 0.000 claims abstract description 65
- -1 enoxolone tristearin alcohol ester Chemical class 0.000 claims abstract description 54
- 230000012010 growth Effects 0.000 claims abstract description 50
- ZWTDXYUDJYDHJR-UHFFFAOYSA-N (E)-1-(2,4-dihydroxyphenyl)-3-(2,4-dihydroxyphenyl)-2-propen-1-one Natural products OC1=CC(O)=CC=C1C=CC(=O)C1=CC=C(O)C=C1O ZWTDXYUDJYDHJR-UHFFFAOYSA-N 0.000 claims abstract description 32
- YQHMWTPYORBCMF-UHFFFAOYSA-N Naringenin chalcone Natural products C1=CC(O)=CC=C1C=CC(=O)C1=C(O)C=C(O)C=C1O YQHMWTPYORBCMF-UHFFFAOYSA-N 0.000 claims abstract description 32
- MPDGHEJMBKOTSU-UHFFFAOYSA-N Glycyrrhetinsaeure Natural products C12C(=O)C=C3C4CC(C)(C(O)=O)CCC4(C)CCC3(C)C1(C)CCC1C2(C)CCC(O)C1(C)C MPDGHEJMBKOTSU-UHFFFAOYSA-N 0.000 claims abstract description 28
- 229960003720 enoxolone Drugs 0.000 claims abstract description 28
- WNIFXKPDILJURQ-UHFFFAOYSA-N stearyl glycyrrhizinate Natural products C1CC(O)C(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C(=O)OCCCCCCCCCCCCCCCCCC)(C)CC5C4=CC(=O)C3C21C WNIFXKPDILJURQ-UHFFFAOYSA-N 0.000 claims abstract description 28
- 239000002994 raw material Substances 0.000 claims abstract description 25
- RGZSQWQPBWRIAQ-LSDHHAIUSA-N alpha-Bisabolol Natural products CC(C)=CCC[C@@](C)(O)[C@@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-LSDHHAIUSA-N 0.000 claims abstract description 24
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims abstract description 23
- WYQVAPGDARQUBT-FGWHUCSPSA-N Madecassol Chemical compound O([C@@H]1[C@@H](CO)O[C@H]([C@@H]([C@H]1O)O)OC[C@H]1O[C@H]([C@@H]([C@@H](O)[C@@H]1O)O)OC(=O)[C@]12CC[C@H]([C@@H]([C@H]1C=1[C@@]([C@@]3(CC[C@H]4[C@](C)(CO)[C@@H](O)[C@H](O)C[C@]4(C)[C@H]3CC=1)C)(C)CC2)C)C)[C@@H]1O[C@@H](C)[C@H](O)[C@@H](O)[C@H]1O WYQVAPGDARQUBT-FGWHUCSPSA-N 0.000 claims abstract description 23
- WYQVAPGDARQUBT-XCWYDTOWSA-N asiaticoside Natural products O=C(O[C@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO[C@H]2[C@H](O)[C@H](O)[C@H](O[C@H]3[C@H](O)[C@H](O)[C@@H](O)[C@H](C)O3)[C@@H](CO)O2)O1)[C@@]12[C@@H]([C@@H](C)[C@H](C)CC1)C=1[C@](C)([C@@]3(C)[C@@H]([C@@]4(C)[C@H]([C@@](CO)(C)[C@@H](O)[C@H](O)C4)CC3)CC=1)CC2 WYQVAPGDARQUBT-XCWYDTOWSA-N 0.000 claims abstract description 23
- 229920000669 heparin Polymers 0.000 claims abstract description 23
- WTVHAMTYZJGJLJ-UHFFFAOYSA-N (+)-(4S,8R)-8-epi-beta-bisabolol Natural products CC(C)=CCCC(C)C1(O)CCC(C)=CC1 WTVHAMTYZJGJLJ-UHFFFAOYSA-N 0.000 claims abstract description 19
- RGZSQWQPBWRIAQ-CABCVRRESA-N (-)-alpha-Bisabolol Chemical compound CC(C)=CCC[C@](C)(O)[C@H]1CCC(C)=CC1 RGZSQWQPBWRIAQ-CABCVRRESA-N 0.000 claims abstract description 19
- 229940036350 bisabolol Drugs 0.000 claims abstract description 19
- HHGZABIIYIWLGA-UHFFFAOYSA-N bisabolol Natural products CC1CCC(C(C)(O)CCC=C(C)C)CC1 HHGZABIIYIWLGA-UHFFFAOYSA-N 0.000 claims abstract description 19
- IKGXIBQEEMLURG-NVPNHPEKSA-N rutin Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 IKGXIBQEEMLURG-NVPNHPEKSA-N 0.000 claims abstract description 19
- 229960003232 troxerutin Drugs 0.000 claims abstract description 18
- 239000000463 material Substances 0.000 claims abstract description 5
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 claims description 26
- POJWUDADGALRAB-UHFFFAOYSA-N allantoin Chemical compound NC(=O)NC1NC(=O)NC1=O POJWUDADGALRAB-UHFFFAOYSA-N 0.000 claims description 24
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 20
- 239000008367 deionised water Substances 0.000 claims description 18
- 229910021641 deionized water Inorganic materials 0.000 claims description 18
- MPDGHEJMBKOTSU-YKLVYJNSSA-N 18beta-glycyrrhetic acid Chemical compound C([C@H]1C2=CC(=O)[C@H]34)[C@@](C)(C(O)=O)CC[C@]1(C)CC[C@@]2(C)[C@]4(C)CC[C@@H]1[C@]3(C)CC[C@H](O)C1(C)C MPDGHEJMBKOTSU-YKLVYJNSSA-N 0.000 claims description 13
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 claims description 13
- CDQSJQSWAWPGKG-UHFFFAOYSA-N butane-1,1-diol Chemical compound CCCC(O)O CDQSJQSWAWPGKG-UHFFFAOYSA-N 0.000 claims description 13
- 235000011187 glycerol Nutrition 0.000 claims description 13
- 229960005323 phenoxyethanol Drugs 0.000 claims description 13
- POJWUDADGALRAB-PVQJCKRUSA-N Allantoin Natural products NC(=O)N[C@@H]1NC(=O)NC1=O POJWUDADGALRAB-PVQJCKRUSA-N 0.000 claims description 12
- 239000003109 Disodium ethylene diamine tetraacetate Substances 0.000 claims description 12
- ZGTMUACCHSMWAC-UHFFFAOYSA-L EDTA disodium salt (anhydrous) Chemical compound [Na+].[Na+].OC(=O)CN(CC([O-])=O)CCN(CC(O)=O)CC([O-])=O ZGTMUACCHSMWAC-UHFFFAOYSA-L 0.000 claims description 12
- 229920002385 Sodium hyaluronate Polymers 0.000 claims description 12
- 229960000458 allantoin Drugs 0.000 claims description 12
- 235000019301 disodium ethylene diamine tetraacetate Nutrition 0.000 claims description 12
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 claims description 12
- 229940010747 sodium hyaluronate Drugs 0.000 claims description 12
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 claims description 12
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims description 9
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 claims description 9
- 229920005573 silicon-containing polymer Polymers 0.000 claims description 9
- 229920001285 xanthan gum Polymers 0.000 claims description 9
- 239000002253 acid Substances 0.000 claims description 8
- 239000000839 emulsion Substances 0.000 claims description 8
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 claims description 7
- 230000001815 facial effect Effects 0.000 claims description 7
- 229930182478 glucoside Natural products 0.000 claims description 7
- 150000008131 glucosides Chemical class 0.000 claims description 7
- SMITZRKODWNNBA-UHFFFAOYSA-N hexadecyl dihydrogen phosphate;potassium Chemical compound [K].CCCCCCCCCCCCCCCCOP(O)(O)=O SMITZRKODWNNBA-UHFFFAOYSA-N 0.000 claims description 7
- 229920001495 poly(sodium acrylate) polymer Polymers 0.000 claims description 7
- 229910052708 sodium Inorganic materials 0.000 claims description 7
- 239000011734 sodium Substances 0.000 claims description 7
- NNMHYFLPFNGQFZ-UHFFFAOYSA-M sodium polyacrylate Chemical compound [Na+].[O-]C(=O)C=C NNMHYFLPFNGQFZ-UHFFFAOYSA-M 0.000 claims description 7
- 239000004094 surface-active agent Substances 0.000 claims description 7
- 229940082500 cetostearyl alcohol Drugs 0.000 claims description 4
- 150000002148 esters Chemical class 0.000 claims description 4
- OULAJFUGPPVRBK-UHFFFAOYSA-N tetratriacontyl alcohol Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCCO OULAJFUGPPVRBK-UHFFFAOYSA-N 0.000 claims description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 3
- 239000004354 Hydroxyethyl cellulose Substances 0.000 claims description 3
- 229920000663 Hydroxyethyl cellulose Polymers 0.000 claims description 3
- 229930182470 glycoside Natural products 0.000 claims description 3
- 150000002338 glycosides Chemical class 0.000 claims description 3
- 235000019447 hydroxyethyl cellulose Nutrition 0.000 claims description 3
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 claims description 2
- 241001122767 Theaceae Species 0.000 claims 5
- 239000004743 Polypropylene Substances 0.000 claims 4
- 229920001155 polypropylene Polymers 0.000 claims 4
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N Phenol Chemical compound OC1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 claims 2
- 150000001336 alkenes Chemical class 0.000 claims 1
- 229940081733 cetearyl alcohol Drugs 0.000 claims 1
- 150000004702 methyl esters Chemical class 0.000 claims 1
- JRZJOMJEPLMPRA-UHFFFAOYSA-N olefin Natural products CCCCCCCC=C JRZJOMJEPLMPRA-UHFFFAOYSA-N 0.000 claims 1
- 229940084106 spermaceti Drugs 0.000 claims 1
- 239000012177 spermaceti Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 27
- DCXXMTOCNZCJGO-UHFFFAOYSA-N Glycerol trioctadecanoate Natural products CCCCCCCCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCCCCCCCC)COC(=O)CCCCCCCCCCCCCCCCC DCXXMTOCNZCJGO-UHFFFAOYSA-N 0.000 abstract description 17
- 239000002537 cosmetic Substances 0.000 abstract description 10
- 231100000241 scar Toxicity 0.000 abstract description 8
- 230000008439 repair process Effects 0.000 abstract description 6
- 239000000287 crude extract Substances 0.000 abstract description 2
- 230000006870 function Effects 0.000 description 48
- 239000012071 phase Substances 0.000 description 40
- 210000003491 skin Anatomy 0.000 description 30
- 239000003921 oil Substances 0.000 description 25
- 235000019198 oils Nutrition 0.000 description 25
- 230000003110 anti-inflammatory effect Effects 0.000 description 14
- 238000011156 evaluation Methods 0.000 description 14
- 206010061218 Inflammation Diseases 0.000 description 12
- BJRNKVDFDLYUGJ-RMPHRYRLSA-N hydroquinone O-beta-D-glucopyranoside Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1=CC=C(O)C=C1 BJRNKVDFDLYUGJ-RMPHRYRLSA-N 0.000 description 12
- 230000004054 inflammatory process Effects 0.000 description 12
- 230000002401 inhibitory effect Effects 0.000 description 12
- 239000000047 product Substances 0.000 description 12
- 102000003425 Tyrosinase Human genes 0.000 description 11
- 108060008724 Tyrosinase Proteins 0.000 description 11
- HVYWMOMLDIMFJA-DPAQBDIFSA-N cholesterol Chemical compound C1C=C2C[C@@H](O)CC[C@]2(C)[C@@H]2[C@@H]1[C@@H]1CC[C@H]([C@H](C)CCCC(C)C)[C@@]1(C)CC2 HVYWMOMLDIMFJA-DPAQBDIFSA-N 0.000 description 10
- 239000000686 essence Substances 0.000 description 10
- 238000002474 experimental method Methods 0.000 description 10
- BEJNERDRQOWKJM-UHFFFAOYSA-N kojic acid Chemical compound OCC1=CC(=O)C(O)=CO1 BEJNERDRQOWKJM-UHFFFAOYSA-N 0.000 description 9
- WZNJWVWKTVETCG-UHFFFAOYSA-N kojic acid Natural products OC(=O)C(N)CN1C=CC(=O)C(O)=C1 WZNJWVWKTVETCG-UHFFFAOYSA-N 0.000 description 9
- 229960004705 kojic acid Drugs 0.000 description 9
- 208000027418 Wounds and injury Diseases 0.000 description 8
- 239000003814 drug Substances 0.000 description 7
- 238000000034 method Methods 0.000 description 7
- 238000002360 preparation method Methods 0.000 description 7
- 239000000523 sample Substances 0.000 description 7
- 206010052428 Wound Diseases 0.000 description 6
- 210000000274 microglia Anatomy 0.000 description 6
- 238000011160 research Methods 0.000 description 6
- 244000269722 Thea sinensis Species 0.000 description 5
- 235000012000 cholesterol Nutrition 0.000 description 5
- 239000000499 gel Substances 0.000 description 5
- 229960002897 heparin Drugs 0.000 description 5
- 238000011282 treatment Methods 0.000 description 5
- 241000196324 Embryophyta Species 0.000 description 4
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 description 4
- 206010030113 Oedema Diseases 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 4
- 230000015572 biosynthetic process Effects 0.000 description 4
- 210000004204 blood vessel Anatomy 0.000 description 4
- 210000004027 cell Anatomy 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 201000010099 disease Diseases 0.000 description 4
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 4
- IRHTZOCLLONTOC-UHFFFAOYSA-N hexacosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCCCCCO IRHTZOCLLONTOC-UHFFFAOYSA-N 0.000 description 4
- 230000002757 inflammatory effect Effects 0.000 description 4
- 239000006210 lotion Substances 0.000 description 4
- 238000012360 testing method Methods 0.000 description 4
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 4
- 239000000341 volatile oil Substances 0.000 description 4
- 241000894006 Bacteria Species 0.000 description 3
- 206010015150 Erythema Diseases 0.000 description 3
- 229930182558 Sterol Natural products 0.000 description 3
- 150000001335 aliphatic alkanes Chemical class 0.000 description 3
- 210000004369 blood Anatomy 0.000 description 3
- 239000008280 blood Substances 0.000 description 3
- 238000004140 cleaning Methods 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 235000013399 edible fruits Nutrition 0.000 description 3
- 235000013305 food Nutrition 0.000 description 3
- 210000004209 hair Anatomy 0.000 description 3
- 206010020718 hyperplasia Diseases 0.000 description 3
- 230000006872 improvement Effects 0.000 description 3
- 230000028709 inflammatory response Effects 0.000 description 3
- 230000000474 nursing effect Effects 0.000 description 3
- 239000001301 oxygen Substances 0.000 description 3
- 229910052760 oxygen Inorganic materials 0.000 description 3
- 210000001732 sebaceous gland Anatomy 0.000 description 3
- 210000002374 sebum Anatomy 0.000 description 3
- 230000028327 secretion Effects 0.000 description 3
- 235000003702 sterols Nutrition 0.000 description 3
- 150000003432 sterols Chemical class 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 210000001519 tissue Anatomy 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 239000008158 vegetable oil Substances 0.000 description 3
- 235000013311 vegetables Nutrition 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 2
- JMGZEFIQIZZSBH-UHFFFAOYSA-N Bioquercetin Natural products CC1OC(OCC(O)C2OC(OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5)C(O)C2O)C(O)C(O)C1O JMGZEFIQIZZSBH-UHFFFAOYSA-N 0.000 description 2
- 241000283153 Cetacea Species 0.000 description 2
- 241000206575 Chondrus crispus Species 0.000 description 2
- 241000186427 Cutibacterium acnes Species 0.000 description 2
- 241000238557 Decapoda Species 0.000 description 2
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 2
- 229920002683 Glycosaminoglycan Polymers 0.000 description 2
- 101000669447 Homo sapiens Toll-like receptor 4 Proteins 0.000 description 2
- 241001071864 Lethrinus laticaudis Species 0.000 description 2
- OVRNDRQMDRJTHS-UHFFFAOYSA-N N-acelyl-D-glucosamine Natural products CC(=O)NC1C(O)OC(CO)C(O)C1O OVRNDRQMDRJTHS-UHFFFAOYSA-N 0.000 description 2
- OVRNDRQMDRJTHS-FMDGEEDCSA-N N-acetyl-beta-D-glucosamine Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O OVRNDRQMDRJTHS-FMDGEEDCSA-N 0.000 description 2
- 241000219784 Sophora Species 0.000 description 2
- 208000007107 Stomach Ulcer Diseases 0.000 description 2
- MUMGGOZAMZWBJJ-DYKIIFRCSA-N Testostosterone Chemical compound O=C1CC[C@]2(C)[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 MUMGGOZAMZWBJJ-DYKIIFRCSA-N 0.000 description 2
- 208000007536 Thrombosis Diseases 0.000 description 2
- 102100039360 Toll-like receptor 4 Human genes 0.000 description 2
- 208000025865 Ulcer Diseases 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 230000000844 anti-bacterial effect Effects 0.000 description 2
- 230000003064 anti-oxidating effect Effects 0.000 description 2
- 230000000259 anti-tumor effect Effects 0.000 description 2
- 230000000767 anti-ulcer Effects 0.000 description 2
- 239000003146 anticoagulant agent Substances 0.000 description 2
- 230000010100 anticoagulation Effects 0.000 description 2
- 230000006907 apoptotic process Effects 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- YZXBAPSDXZZRGB-DOFZRALJSA-N arachidonic acid Chemical compound CCCCC\C=C/C\C=C/C\C=C/C\C=C/CCCC(O)=O YZXBAPSDXZZRGB-DOFZRALJSA-N 0.000 description 2
- 206010003246 arthritis Diseases 0.000 description 2
- 229940022757 asiaticoside Drugs 0.000 description 2
- QCYLIQBVLZBPNK-UHFFFAOYSA-N asiaticoside A Natural products O1C(C(=O)C(C)C)=CC(C)C(C2(C(OC(C)=O)CC34C5)C)C1CC2(C)C3CCC(C1(C)C)C45CCC1OC1OCC(O)C(O)C1O QCYLIQBVLZBPNK-UHFFFAOYSA-N 0.000 description 2
- 239000012496 blank sample Substances 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 230000008859 change Effects 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 2
- 230000008030 elimination Effects 0.000 description 2
- 238000003379 elimination reaction Methods 0.000 description 2
- 239000003995 emulsifying agent Substances 0.000 description 2
- 210000002889 endothelial cell Anatomy 0.000 description 2
- 230000002708 enhancing effect Effects 0.000 description 2
- IVTMALDHFAHOGL-UHFFFAOYSA-N eriodictyol 7-O-rutinoside Natural products OC1C(O)C(O)C(C)OC1OCC1C(O)C(O)C(O)C(OC=2C=C3C(C(C(O)=C(O3)C=3C=C(O)C(O)=CC=3)=O)=C(O)C=2)O1 IVTMALDHFAHOGL-UHFFFAOYSA-N 0.000 description 2
- 231100000321 erythema Toxicity 0.000 description 2
- 201000005917 gastric ulcer Diseases 0.000 description 2
- 238000001631 haemodialysis Methods 0.000 description 2
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 2
- JYGXADMDTFJGBT-VWUMJDOOSA-N hydrocortisone Chemical compound O=C1CC[C@]2(C)[C@H]3[C@@H](O)C[C@](C)([C@@](CC4)(O)C(=O)CO)[C@@H]4[C@@H]3CCC2=C1 JYGXADMDTFJGBT-VWUMJDOOSA-N 0.000 description 2
- 230000001976 improved effect Effects 0.000 description 2
- 208000015181 infectious disease Diseases 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 208000014674 injury Diseases 0.000 description 2
- 150000002617 leukotrienes Chemical class 0.000 description 2
- 235000012054 meals Nutrition 0.000 description 2
- 230000010534 mechanism of action Effects 0.000 description 2
- 210000002752 melanocyte Anatomy 0.000 description 2
- 230000004060 metabolic process Effects 0.000 description 2
- 210000001616 monocyte Anatomy 0.000 description 2
- 229950006780 n-acetylglucosamine Drugs 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 2
- 230000008092 positive effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- 239000003755 preservative agent Substances 0.000 description 2
- 230000002335 preservative effect Effects 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 229940055019 propionibacterium acne Drugs 0.000 description 2
- 150000003180 prostaglandins Chemical class 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- FDRQPMVGJOQVTL-UHFFFAOYSA-N quercetin rutinoside Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC=2C(C3=C(O)C=C(O)C=C3OC=2C=2C=C(O)C(O)=CC=2)=O)O1 FDRQPMVGJOQVTL-UHFFFAOYSA-N 0.000 description 2
- 150000003254 radicals Chemical class 0.000 description 2
- ALABRVAAKCSLSC-UHFFFAOYSA-N rutin Natural products CC1OC(OCC2OC(O)C(O)C(O)C2O)C(O)C(O)C1OC3=C(Oc4cc(O)cc(O)c4C3=O)c5ccc(O)c(O)c5 ALABRVAAKCSLSC-UHFFFAOYSA-N 0.000 description 2
- 235000005493 rutin Nutrition 0.000 description 2
- 229960004555 rutoside Drugs 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- 230000001953 sensory effect Effects 0.000 description 2
- 210000004927 skin cell Anatomy 0.000 description 2
- 208000010110 spontaneous platelet aggregation Diseases 0.000 description 2
- 238000006467 substitution reaction Methods 0.000 description 2
- 238000003786 synthesis reaction Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- 239000002562 thickening agent Substances 0.000 description 2
- 231100000397 ulcer Toxicity 0.000 description 2
- 230000002087 whitening effect Effects 0.000 description 2
- 230000029663 wound healing Effects 0.000 description 2
- KIUKXJAPPMFGSW-DNGZLQJQSA-N (2S,3S,4S,5R,6R)-6-[(2S,3R,4R,5S,6R)-3-Acetamido-2-[(2S,3S,4R,5R,6R)-6-[(2R,3R,4R,5S,6R)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2-carboxylic acid Chemical compound CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 KIUKXJAPPMFGSW-DNGZLQJQSA-N 0.000 description 1
- MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
- YRWKOPNMRTVMFZ-UHFFFAOYSA-N 1-[4-(1,2-dihydroxyethyl)-2,5-dioxoimidazolidin-4-yl]-3-[[[4-(hydroxymethyl)-2,5-dioxoimidazolidin-4-yl]carbamoylamino]methyl]urea Chemical compound OCC(O)C1(NC(=O)NCNC(=O)NC2(CO)NC(=O)NC2=O)NC(=O)NC1=O YRWKOPNMRTVMFZ-UHFFFAOYSA-N 0.000 description 1
- PXFBZOLANLWPMH-UHFFFAOYSA-N 16-Epiaffinine Natural products C1C(C2=CC=CC=C2N2)=C2C(=O)CC2C(=CC)CN(C)C1C2CO PXFBZOLANLWPMH-UHFFFAOYSA-N 0.000 description 1
- VCNKUCWWHVTTBY-UHFFFAOYSA-N 18alpha-Oleanane Natural products C1CCC(C)(C)C2CCC3(C)C4(C)CCC5(C)CCC(C)(C)CC5C4CCC3C21C VCNKUCWWHVTTBY-UHFFFAOYSA-N 0.000 description 1
- IYVFNTXFRYQLRP-VVSTWUKXSA-N 2-[3,4-bis(2-hydroxyethoxy)phenyl]-5-hydroxy-7-(2-hydroxyethoxy)-3-{[(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-({[(2r,3r,4r,5r,6s)-3,4,5-trihydroxy-6-methyloxan-2-yl]oxy}methyl)oxan-2-yl]oxy}-4h-chromen-4-one Chemical compound O[C@@H]1[C@H](O)[C@@H](O)[C@H](C)O[C@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@H](OC=2C(C3=C(O)C=C(OCCO)C=C3OC=2C=2C=C(OCCO)C(OCCO)=CC=2)=O)O1 IYVFNTXFRYQLRP-VVSTWUKXSA-N 0.000 description 1
- OMIGHNLMNHATMP-UHFFFAOYSA-N 2-hydroxyethyl prop-2-enoate Chemical compound OCCOC(=O)C=C OMIGHNLMNHATMP-UHFFFAOYSA-N 0.000 description 1
- 229940100555 2-methyl-4-isothiazolin-3-one Drugs 0.000 description 1
- UBLAMKHIFZBBSS-UHFFFAOYSA-N 3-Methylbutyl pentanoate Chemical compound CCCCC(=O)OCCC(C)C UBLAMKHIFZBBSS-UHFFFAOYSA-N 0.000 description 1
- IOYNGCZNYGEZRO-UHFFFAOYSA-N 3-ethyl-n,n,2-trimethyl-1h-indol-5-amine Chemical compound C1=C(N(C)C)C=C2C(CC)=C(C)NC2=C1 IOYNGCZNYGEZRO-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 206010002198 Anaphylactic reaction Diseases 0.000 description 1
- 206010002383 Angina Pectoris Diseases 0.000 description 1
- 102000004411 Antithrombin III Human genes 0.000 description 1
- 108090000935 Antithrombin III Proteins 0.000 description 1
- 206010003211 Arteriosclerosis coronary artery Diseases 0.000 description 1
- 208000006820 Arthralgia Diseases 0.000 description 1
- 244000025254 Cannabis sativa Species 0.000 description 1
- 208000024172 Cardiovascular disease Diseases 0.000 description 1
- 241000167550 Centella Species 0.000 description 1
- 241000288570 Chionochloa conspicua Species 0.000 description 1
- 102000008186 Collagen Human genes 0.000 description 1
- 208000036828 Device occlusion Diseases 0.000 description 1
- 241000360590 Erythrites Species 0.000 description 1
- 206010063560 Excessive granulation tissue Diseases 0.000 description 1
- 102000009123 Fibrin Human genes 0.000 description 1
- 108010073385 Fibrin Proteins 0.000 description 1
- BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
- 230000010337 G2 phase Effects 0.000 description 1
- 206010061216 Infarction Diseases 0.000 description 1
- 108090001005 Interleukin-6 Proteins 0.000 description 1
- 108010025252 Kassinin Proteins 0.000 description 1
- 208000002260 Keloid Diseases 0.000 description 1
- 206010023330 Keloid scar Diseases 0.000 description 1
- 239000004367 Lipase Substances 0.000 description 1
- 102000004882 Lipase Human genes 0.000 description 1
- 108090001060 Lipase Proteins 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 206010030012 Occupational dermatitis Diseases 0.000 description 1
- 229920002690 Polyoxyl 40 HydrogenatedCastorOil Polymers 0.000 description 1
- 102000004005 Prostaglandin-endoperoxide synthases Human genes 0.000 description 1
- 108090000459 Prostaglandin-endoperoxide synthases Proteins 0.000 description 1
- 241000220324 Pyrus Species 0.000 description 1
- 235000019774 Rice Bran oil Nutrition 0.000 description 1
- 102000012479 Serine Proteases Human genes 0.000 description 1
- 108010022999 Serine Proteases Proteins 0.000 description 1
- 229920002125 Sokalan® Polymers 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 1
- 241000700647 Variola virus Species 0.000 description 1
- 241000700605 Viruses Species 0.000 description 1
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 238000004847 absorption spectroscopy Methods 0.000 description 1
- 150000001242 acetic acid derivatives Chemical class 0.000 description 1
- 125000003647 acryloyl group Chemical group O=C([*])C([H])=C([H])[H] 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 238000011360 adjunctive therapy Methods 0.000 description 1
- 210000004404 adrenal cortex Anatomy 0.000 description 1
- 159000000013 aluminium salts Chemical class 0.000 description 1
- 229910000329 aluminium sulfate Inorganic materials 0.000 description 1
- 230000036783 anaphylactic response Effects 0.000 description 1
- 208000003455 anaphylaxis Diseases 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940124599 anti-inflammatory drug Drugs 0.000 description 1
- 230000001857 anti-mycotic effect Effects 0.000 description 1
- 230000001028 anti-proliverative effect Effects 0.000 description 1
- 230000002785 anti-thrombosis Effects 0.000 description 1
- 229940127219 anticoagulant drug Drugs 0.000 description 1
- 239000002543 antimycotic Substances 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 229960005348 antithrombin iii Drugs 0.000 description 1
- 239000003699 antiulcer agent Substances 0.000 description 1
- 229940114079 arachidonic acid Drugs 0.000 description 1
- 235000021342 arachidonic acid Nutrition 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 230000008827 biological function Effects 0.000 description 1
- 230000017531 blood circulation Effects 0.000 description 1
- 230000023555 blood coagulation Effects 0.000 description 1
- 238000009835 boiling Methods 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 230000004856 capillary permeability Effects 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 230000022131 cell cycle Effects 0.000 description 1
- 208000026106 cerebrovascular disease Diseases 0.000 description 1
- 208000019065 cervical carcinoma Diseases 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 230000003399 chemotactic effect Effects 0.000 description 1
- AQIXAKUUQRKLND-UHFFFAOYSA-N cimetidine Chemical compound N#C/N=C(/NC)NCCSCC=1N=CNC=1C AQIXAKUUQRKLND-UHFFFAOYSA-N 0.000 description 1
- 230000004087 circulation Effects 0.000 description 1
- 229920001436 collagen Polymers 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000002131 composite material Substances 0.000 description 1
- 150000001875 compounds Chemical class 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 229920001577 copolymer Polymers 0.000 description 1
- 210000000736 corneocyte Anatomy 0.000 description 1
- 208000029078 coronary artery disease Diseases 0.000 description 1
- 208000026758 coronary atherosclerosis Diseases 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 238000005260 corrosion Methods 0.000 description 1
- 229940117173 croton oil Drugs 0.000 description 1
- 239000007854 depigmenting agent Substances 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- JZZIHCLFHIXETF-UHFFFAOYSA-N dimethylsilicon Chemical compound C[Si]C JZZIHCLFHIXETF-UHFFFAOYSA-N 0.000 description 1
- 231100000673 dose–response relationship Toxicity 0.000 description 1
- 208000000718 duodenal ulcer Diseases 0.000 description 1
- 230000002526 effect on cardiovascular system Effects 0.000 description 1
- 210000003038 endothelium Anatomy 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 210000000981 epithelium Anatomy 0.000 description 1
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 230000032050 esterification Effects 0.000 description 1
- 238000005886 esterification reaction Methods 0.000 description 1
- 229960001617 ethyl hydroxybenzoate Drugs 0.000 description 1
- NUVBSKCKDOMJSU-UHFFFAOYSA-N ethylparaben Chemical compound CCOC(=O)C1=CC=C(O)C=C1 NUVBSKCKDOMJSU-UHFFFAOYSA-N 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 235000019197 fats Nutrition 0.000 description 1
- 229950003499 fibrin Drugs 0.000 description 1
- 230000020764 fibrinolysis Effects 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 238000004508 fractional distillation Methods 0.000 description 1
- 208000001130 gallstones Diseases 0.000 description 1
- 150000002342 glycyrrhetinic acids Chemical class 0.000 description 1
- 210000001126 granulation tissue Anatomy 0.000 description 1
- 239000004519 grease Substances 0.000 description 1
- 210000003780 hair follicle Anatomy 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 230000036541 health Effects 0.000 description 1
- 208000019622 heart disease Diseases 0.000 description 1
- 230000000322 hemodialysis Effects 0.000 description 1
- 208000006454 hepatitis Diseases 0.000 description 1
- 238000004128 high performance liquid chromatography Methods 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- 235000003642 hunger Nutrition 0.000 description 1
- 229920002674 hyaluronan Polymers 0.000 description 1
- 229960003160 hyaluronic acid Drugs 0.000 description 1
- 230000036571 hydration Effects 0.000 description 1
- 238000006703 hydration reaction Methods 0.000 description 1
- 229960000890 hydrocortisone Drugs 0.000 description 1
- 230000007062 hydrolysis Effects 0.000 description 1
- 238000006460 hydrolysis reaction Methods 0.000 description 1
- 230000000774 hypoallergenic effect Effects 0.000 description 1
- SIOMFBXUIJKTMF-UHFFFAOYSA-N hypoglauterpenic acid Natural products C1CC(O)C(C)(C)C2=CCC3(C)C4(C)CCC5(C(O)=O)CCC(C)(C)CC5C4=CCC3C21C SIOMFBXUIJKTMF-UHFFFAOYSA-N 0.000 description 1
- 230000036737 immune function Effects 0.000 description 1
- 239000002955 immunomodulating agent Substances 0.000 description 1
- 230000002584 immunomodulator Effects 0.000 description 1
- 229940121354 immunomodulator Drugs 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002779 inactivation Effects 0.000 description 1
- 230000001939 inductive effect Effects 0.000 description 1
- 230000007574 infarction Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 238000007689 inspection Methods 0.000 description 1
- 210000004347 intestinal mucosa Anatomy 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 229910052740 iodine Inorganic materials 0.000 description 1
- 210000001117 keloid Anatomy 0.000 description 1
- 238000003475 lamination Methods 0.000 description 1
- 235000019421 lipase Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 235000013310 margarine Nutrition 0.000 description 1
- 239000003264 margarine Substances 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- KRPAJLYSLFNDOA-UHFFFAOYSA-N mephenesin carbamate Chemical compound CC1=CC=CC=C1OCC(O)COC(N)=O KRPAJLYSLFNDOA-UHFFFAOYSA-N 0.000 description 1
- 229950006838 mephenesin carbamate Drugs 0.000 description 1
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 1
- 229910052751 metal Inorganic materials 0.000 description 1
- 239000002184 metal Substances 0.000 description 1
- ZGEGCLOFRBLKSE-UHFFFAOYSA-N methylene hexane Natural products CCCCCC=C ZGEGCLOFRBLKSE-UHFFFAOYSA-N 0.000 description 1
- BEGLCMHJXHIJLR-UHFFFAOYSA-N methylisothiazolinone Chemical compound CN1SC=CC1=O BEGLCMHJXHIJLR-UHFFFAOYSA-N 0.000 description 1
- 230000004089 microcirculation Effects 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 239000003595 mist Substances 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 125000002950 monocyclic group Chemical group 0.000 description 1
- 210000000865 mononuclear phagocyte system Anatomy 0.000 description 1
- 230000015604 muscle hyperplasia Effects 0.000 description 1
- 239000005445 natural material Substances 0.000 description 1
- 229930014626 natural product Natural products 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 235000014571 nuts Nutrition 0.000 description 1
- GYCKQBWUSACYIF-UHFFFAOYSA-N o-hydroxybenzoic acid ethyl ester Natural products CCOC(=O)C1=CC=CC=C1O GYCKQBWUSACYIF-UHFFFAOYSA-N 0.000 description 1
- 230000009965 odorless effect Effects 0.000 description 1
- BPAWXSVOAOLSRP-UHFFFAOYSA-N oleanane Natural products CCCCCCCCCCCCCCCC(=O)OC1CCC2(C)C(CCC3(C)C2CC=C4C5CC(C)(C)CCC5(C)C(O)CC34C)C1(C)C BPAWXSVOAOLSRP-UHFFFAOYSA-N 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003287 optical effect Effects 0.000 description 1
- NMHMNPHRMNGLLB-UHFFFAOYSA-N p-hydroxybenzene propanoic acid Natural products OC(=O)CCC1=CC=C(O)C=C1 NMHMNPHRMNGLLB-UHFFFAOYSA-N 0.000 description 1
- 235000021017 pears Nutrition 0.000 description 1
- 230000000149 penetrating effect Effects 0.000 description 1
- 230000035699 permeability Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 235000002378 plant sterols Nutrition 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002062 proliferating effect Effects 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- ULWHHBHJGPPBCO-UHFFFAOYSA-N propane-1,1-diol Chemical class CCC(O)O ULWHHBHJGPPBCO-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 1
- 229960003415 propylparaben Drugs 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 238000012827 research and development Methods 0.000 description 1
- 201000003068 rheumatic fever Diseases 0.000 description 1
- 239000008165 rice bran oil Substances 0.000 description 1
- 229930004725 sesquiterpene Natural products 0.000 description 1
- 150000004354 sesquiterpene derivatives Chemical group 0.000 description 1
- 230000009759 skin aging Effects 0.000 description 1
- 208000017520 skin disease Diseases 0.000 description 1
- 201000010106 skin squamous cell carcinoma Diseases 0.000 description 1
- 210000002460 smooth muscle Anatomy 0.000 description 1
- 159000000000 sodium salts Chemical class 0.000 description 1
- 241000894007 species Species 0.000 description 1
- 150000003431 steroids Chemical class 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 1
- 239000013589 supplement Substances 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 229960003604 testosterone Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 230000000451 tissue damage Effects 0.000 description 1
- 231100000827 tissue damage Toxicity 0.000 description 1
- 230000001256 tonic effect Effects 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 210000003606 umbilical vein Anatomy 0.000 description 1
- 230000002792 vascular Effects 0.000 description 1
- 235000019871 vegetable fat Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 239000011647 vitamin D3 Substances 0.000 description 1
- 150000003722 vitamin derivatives Chemical class 0.000 description 1
- 230000037314 wound repair Effects 0.000 description 1
- 239000000811 xylitol Substances 0.000 description 1
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 1
- 235000010447 xylitol Nutrition 0.000 description 1
- 229960002675 xylitol Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/92—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof
- A61K8/922—Oils, fats or waxes; Derivatives thereof, e.g. hydrogenation products thereof of vegetable origin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/12—Ketones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7008—Compounds having an amino group directly attached to a carbon atom of the saccharide radical, e.g. D-galactosamine, ranimustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7024—Esters of saccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
- A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
- A61K31/704—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin attached to a condensed carbocyclic ring system, e.g. sennosides, thiocolchicosides, escin, daunorubicin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/34—Alcohols
- A61K8/342—Alcohols having more than seven atoms in an unbroken chain
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/35—Ketones, e.g. benzophenone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/33—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing oxygen
- A61K8/37—Esters of carboxylic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/602—Glycosides, e.g. rutin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/60—Sugars; Derivatives thereof
- A61K8/604—Alkylpolyglycosides; Derivatives thereof, e.g. esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/72—Cosmetics or similar toiletry preparations characterised by the composition containing organic macromolecular compounds
- A61K8/73—Polysaccharides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/10—General cosmetic use
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Birds (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Molecular Biology (AREA)
- Emergency Medicine (AREA)
- Dermatology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
The present invention relates to a kind of composition with anti-acne trace and suppression acne growth function and its application, said composition to include component A and B component, and wherein component A includes following raw material：0.1~1 part of 0.1~1 part of phytosterol, 0.1~2 part of bisabolol and enoxolone tristearin alcohol ester；B component includes：0.1~2 part of 0.1~1 part of phloretin, 0.5~5 part of acetyl chitosamine, 0.05~1 part of liquaemin, 0.1~1 part of asiaticosid and Troxerutin；Component A and B component ratio are 0.3~3：0.85~10.It is characteristic of the invention that all raw materials are embodied in China《Approved uses cosmetic material catalogue》Avoid that anti-acne trace product dosage is big, during slowly effect, anti-acne trace and the problem of long new acne preparing using Plant crude extract, anti-acne trace product prepared by the present invention, which has, to be eliminated red acne print, subtracts light black acne print, repair acne scar and the function for the generation for suppressing new acne.
Description
Technical field
The present invention relates to cosmetic field, and in particular to a kind of cosmetics with anti-acne trace and suppression acne systematic function
Composition and its application.
Background technology
Pockmark is also known as acne scar, is that body repairs reaction to a kind of caused by tissue damage, when the damage depth and corium of skin
, will be by corium fabric cell or the skin blemish of large area, the epidermis at the position can not regenerate, the blood vessel institute of collagen and hyperplasia
Substitution, so there have been pockmark.Pockmark is because infection inflammation or external force extruding are formed, often because being sent out in whelk
As when do not obtain appropriate treatment in time, the inflammatory response of Skin Cell causes the destruction to skin histology, causes scar
The generation of trace.Because the species of whelk is of all kinds, so the form of youth pockmark also has a lot of kinds, and during whelk breaking-out
Inflammatory response it is more serious, skin histology also destroys more severe；The position of inflammation is deeper, and skin histology is also more destroyed
Deep, the pockmark that may be left in the future is also more serious.
Acne print be whelk breaking-out when cause blood vessel dilatation, whelk disappear down after blood vessel can't contract down at once, just
Some average red erythema are formd (to be commonly called as：Red seal), and the inflammatory response of Skin Cell causes and skin histology is broken
Bad, the pigementation after inflammation can make the place for growing red small pox leave black dirty color (to be commonly called as：Black print), thus shape
Into acne print.
Pockmark herein includes acne scar and acne print.
Acne refers to whelk, is being commonly called as acne, also known as " dark sore ", " acne ", and the generation of acne is mainly and sebum secretion
Excessively, pilosebaceous duct block, the factor such as bacterium infection and inflammatory reaction it is closely related.Adolesce male in descendant's body
The rapid rise of level of hormone particularly testosterone, promotes sebaceous glands to develop and produce a large amount of sebums.Pilosebaceous duct simultaneously
Dyskeratosis cause catheter blockage, dyssebacia, it is micro mist thorn to form horn plug.Multiple-microorganism is especially in hair follicle
Propionibacterium acnes amount reproduction, lipase caused by propionibacterium acnes decomposes sebum generation free fatty, while chemotactic is scorching
Disease cell and medium, finally induce and aggravate inflammatory reaction.
The content of the invention
The technical problems to be solved by the invention are to provide a kind of combination with anti-acne trace and suppression acne systematic function
Thing, said composition are prepared with the high-purity raw composition of natural origin, and all raw materials of the invention are embodied in China《
Approval uses cosmetic material catalogue》, have and eliminate red acne print, subtract light black acne print, repair acne scar and suppress new acne life
Into the effect of.
Another technical problem to be solved by this invention is that this kind has anti-acne trace and suppress the group of acne systematic function
Application of the compound in skin care applications.
The technical scheme that the present invention solves above-mentioned technical problem is as follows：One kind has anti-acne trace and suppresses acne growth function
Composition, including component A and B component,
The component A includes the raw material of following parts by weight：0.1~1 part of phytosterol, 0.1~2 part of bisabolol and radix glycyrrhizae
0.1~1 part of hypo acid tristearin alcohol ester；
The B component includes the raw material of following parts by weight：0.1~1 part of phloretin, 0.5~5 part of acetyl chitosamine, heparin
0.1~2 part of 0.05~1 part of sodium, 0.1~1 part of asiaticosid and Troxerutin；
Component A and B component weight ratio are 0.3~3：0.85~10.
The beneficial effects of the invention are as follows：It is characteristic of the invention that all raw materials are embodied in China《Approved uses cosmetic
Product raw material catalogue》, prepared with the high-purity raw composition of natural origin, avoid producing to prepare anti-acne trace using Plant crude extract
Product dosage is big, during slowly effect, anti-acne trace again long new acne the problem of, anti-acne trace product prepared by the present invention, which has, eliminates red acne
Print, subtract light black acne print, repair acne scar and suppress the function of the generation of new acne.
On the basis of above-mentioned technical proposal, currently preferred technical scheme is as follows：
Preferably, a kind of composition with anti-acne trace and suppression acne growth function, including component A and B component,
The component A includes the raw material of following parts by weight：0.2~1 part of phytosterol, 0.1~1 part of bisabolol and radix glycyrrhizae
0.1~0.5 part of hypo acid tristearin alcohol ester；
The B component includes the raw material of following parts by weight：0.1~1 part of phloretin, 0.5~4 part of acetyl chitosamine, heparin
0.1~20 part of 0.05~0.5 part of sodium, 0.1~1 part of asiaticosid and Troxerutin；
Component A and B component weight ratio are 0.4~2.5：0.85~8.5.
Preferably, a kind of composition with anti-acne trace and suppression acne growth function, including component A and B component,
The component A includes the raw material of following parts by weight：0.5 part of phytosterol, 0.5 part of bisabolol and enoxolone are hard
0.5 part of lipidol ester；
The B component includes the raw material of following parts by weight：0.5 part of phloretin, 3 parts of acetyl chitosamine, 0.5 part of liquaemin,
1.5 parts of 0.5 part of asiaticosid and Troxerutin；
Component A and B component weight ratio are 1.5:6.
Application of the composition with anti-acne trace and suppression acne growth function on skin nursing products.
Preferably, a kind of creme with anti-acne trace and suppression acne growth function, every 100 parts by weight creme includes following
Oily molten phase component and water-soluble phase component：
The molten phase component of oil：Including 2.0 parts of component A in such as claim 1, in addition to 3 parts of cetearyl glucoside, whale
0.5 part of ceryl alcohol phosphate potassium, 4 parts of tea leaf oil, 1.8 parts of cetostearyl alcohol, 0.1 part of Vitwas E and polydimethylsiloxanes
1 part of alkane,
Water-soluble phase component：Including 7.0 parts of B component in such as claim 1, in addition to disodium ethylene diamine tetraacetate 0.05
Part, 0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, 0.3 part of Sodium Polyacrylate, 0.1 part of xanthans, Sodium Hyaluronate 0.05
Part, 0.4 part of Phenoxyethanol, 0.2 part of methyl hydroxybenzoate and 0.05 part of essence,
Surplus is supplied with deionized water.
On the basis of above-mentioned technical proposal, the composition of the present invention with anti-acne trace and suppression acne growth function
Application on skin nursing products are prepared is as follows：
A kind of emulsion with anti-acne trace and suppression acne growth function, every 100 parts by weight emulsion include the following molten phase of oil
Component and water-soluble phase component：
The molten phase component of oil：Including 1.5 parts of component A in such as claim 1, in addition to 1.5 parts of cetearyl glucoside,
0.3 part of Phosphoric acid monohexadecyl ester potassium, 2 parts of tea leaf oil, 0.8 part of cetostearyl alcohol, 0.1 part of Vitwas E and poly dimethyl silicon
1 part of oxygen alkane,
Water-soluble phase component：Including 4.0 parts of B component in such as claim 1, in addition to disodium ethylene diamine tetraacetate 0.05
Part, 0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, 0.2 part of Sodium Polyacrylate, 0.1 part of xanthans, Sodium Hyaluronate 0.05
Part, 0.4 part of Phenoxyethanol, 0.2 part of methyl hydroxybenzoate and 0.05 part of essence,
Surplus is supplied with deionized water.
A kind of Essence with anti-acne trace and suppression acne growth function, every 100 parts by weight Essence include following oil
Molten phase component and water-soluble phase component：
The molten phase component of oil：Including 3.0 parts of component A in such as claim 1, in addition to 0.5 part of hydrolecithin, cetanol
1 part of 0.1 part of phosphate potassium, 1 part of tea leaf oil, 0.1 part of Vitwas E and dimethyl silicone polymer,
Water-soluble phase component：Including 9.0 parts of B component in such as claim 1, in addition to disodium ethylene diamine tetraacetate 0.05
Part, 0.2 part of allantoin, 8 parts of glycerine, 4 parts of butanediol, 0.5 part of Sodium Polyacrylate, 0.1 part of xanthans, 0.1 part of Sodium Hyaluronate,
0.2 part of 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,
Surplus is supplied with deionized water.
A kind of gel with anti-acne trace and suppression acne growth function, every 100 parts by weight gel include the following molten phase of oil
Component and water-soluble phase component：
The molten phase component of oil：Including 0.8 part of component A in such as claim 1, in addition to 0.5 part of hydrolecithin, cetanol
0.5 part of 0.1 part of phosphate potassium, 1 part of tea leaf oil, 0.1 part of Vitwas E and dimethyl silicone polymer,
Water-soluble phase component：Including 2.2 parts of B component in such as claim 1, in addition to 0.5 part of disodium ethylene diamine tetraacetate,
0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, 0.6 part of Sodium Polyacrylate, 0.05 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol
With 0.2 part of methyl hydroxybenzoate,
Surplus is supplied with deionized water.
A kind of surfactant with anti-acne trace and suppression acne growth function, every 100 parts by weight surfactant include following oil
Molten phase component and water-soluble phase component：
The molten phase component of oil：Including 0.3 part of component A in such as claim 1, in addition to 0.3 part of hydrolecithin, vitamin
0.5 part of 0.05 part of E acetates and penta dimethyl silicone polymer of ring,
Water-soluble phase component：Including 3.8 parts of B component in such as claim 1, in addition to disodium ethylene diamine tetraacetate 0.05
Part, 0.1 part of allantoin, 5 parts of glycerine, 4 parts of butanediol, 0.2 part of Sodium Polyacrylate, 0.2 part of xanthans, Sodium Hyaluronate 0.05
0.2 part of part, 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,
Surplus is supplied with deionized water.
A kind of facial mask with anti-acne trace and suppression acne growth function, every 100 parts by weight facial mask include the following molten phase of oil
Component and water-soluble phase component：
The molten phase component of oil：Including 0.4 part of component A in such as claim 1, in addition to 3 parts of cetearyl glucoside, whale
0.5 part of ceryl alcohol phosphate potassium, 4 parts of tea leaf oil, 1.8 parts of cetostearyl alcohol, 0.1 part of Vitwas E and polydimethylsiloxanes
1 part of alkane,
Water-soluble phase component：Including 0.85 part of B component in such as claim 1, in addition to disodium ethylene diamine tetraacetate 0.05
Part, 0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, 0.3 part of Sodium Polyacrylate, 0.3 part of hydroxyethyl cellulose, Sodium Hyaluronate
0.2 part of 0.05 part, 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,
Surplus is supplied with deionized water.
Using the invention has the advantages that being：
The combination derives from natural products：It is entitled from Brazilian one kind that phytosterol is taken from vegetable fat, bisabolol
Extracted in the essential oil of Candeia trees, enoxolone tristearin alcohol ester is taken from radix glycyrrhizae, phloretin takes from apple skin and apple
Root (or artificial synthesized), acetyl chitosamine are taken from the shell of shrimp crab, liquaemin is taken from chitterlings, asiaticosid is taken from accumulated snow
Grass, Troxerutin derive from sophora flower, and the content of every kind of composition is more than 95%.
The active component of cosmetic composition of the present invention is prepared, there is following effect and feature：
Phytosterol (phytosterol orplant sterol) is a kind of active component in plant, is widely present in
In each vegetable oil, nut, vegetable seeds, vegetable and fruit, therefore, people can be obtained by phytosterol from daily meals
Supplement, it is a kind of important natural Exploitation of Sterol Resources.The horizontal phytosterol of the usual meals of people is about 200~400mg/g,
The food mainly supplied has vegetable oil, margarine, vegetables and fruits, in vegetable oil, with rice bran oil content of phytosterol highest.Plant
Sterol is sterid, and its chemical constitution and biological function are similar to cholesterol, and side chain is only that in place of both differences, can
Reduction for internal cholesterol.In addition, phytosterol also has the function such as anticancer, anti-inflammatory, anti-oxidant, it has been widely used
In industries such as food, pharmacy, health products.In recent years, imitated by the way that food ingredients are analysed scientifically with the relevant physiology with phytosterol
The continuous development that should be studied, particularly phytosterol healthcare function understanding is deepened constantly, makes phytosterol research and development gradually into focus,
Functional plants sterol food industries are also fast-developing.
Phytosterol has stronger antiinflammatory action to human body, has absorption, the promotion that can suppress human body to cholesterol
The effects such as the katabolism of cholesterol, the biochemical synthesis for suppressing cholesterol.For prophylactic treatment coronary atherosclerosis class
Heart disease, there is the effect of obvious to treatment ulcer, Skin Squamous Cell Carcinoma, cervical carcinoma phytosterol etc.；Wound healing can be promoted, make muscle
Hyperplasia, enhancing capillary circulation；It is alternatively arranged as the inhibitor of gall stone formation.Phytosterol or important steroid drugs and
Vitamin D3Raw materials for production.Phytosterol has very high permeability to skin, can keep skin surface moisture content, promotes skin
Skin metabolism, suppress scytitis, can anti-sunburn, skin aging, also hair tonic, hair care the effect of.
α-bisabol (Vanillomopsis erythropapa) is a kind of to be carried from Brazilian trees Candeia essential oil
The natural component taken out.Natural α-bisabol is fractionated from essential oil：Fractional distillation process is according to the boiling point of different component
Separate the components into out from liquid mixture.Contain (-) α-myrrh Alkanol isomer no less than 95% in final products, generally
Content is 98%.Research shows that only (-) α-myrrh Alkanol isomer is active.Bisabol has unique anti-inflammatory, anti-corrosion, relaxed
Slow, anti-inflammatory, antimycotic, antibacterial activity, the nursing especially suitable for sensitiveness skin.
The bisabol of natural origin:CANDEIA trees are a kind of tropical shrubs for belonging to composite family, be grown on southeast Brazil and
The Cerrado thick forests of Midwest and thick grass area.The trunk of this tree is white, hard, interior resinous.Leaf and lace are fragrant
Taste, and there is medical value.Essential oil is from wooden middle extraction.It is sesquiterpene structure (Fig.3) in α-bisabol, this knot
Structure is found by Isaac et al.This be it is a kind of be fractionated from natural material have optical activity, monocyclic, insatiable hunger
The sesquiterpene alcohols of sum.IUPAC titles:(2S) -6- methyl -2- ((1S) -4- methyl -3- cyclohexenyl groups) -5- heptene -2- alcohol.
Anti-inflammatory activity：In inflammation generating process, monocyte leaves blood and is partly into inflammation as Premeabilisation of cells
In the tissue that disease occurs.Inflammation point endothelial cell tissue can adhere to molecule monocyte, and then they pass through endothelium
Enter along inflammatory signals in tissue.In the metabolin of arachidonic acid lamination, such as leukotriene, prostaglandin and oxygen radical
Play critically important role.
α-bisabol mechanism of action：The effect of α-bisabol is by suppressing 5- LOXs and cyclooxygenase, so as to press down
The generation of leukotriene and prostaglandin processed.
Pharmacology：
Janku and Zita, which determines bisabolol, has the affine performance for suppressing various inflammation and skin.
Later investigation shows that it suppresses the important results of various inflammation growths, experiment in a manner of data statistics
It is Guinea piggy and mouse is object, studies and tested on the edema of formalin and protein.
Other experimental models：
1st, the inflammatory of Irish moss edema is tested with mouse
2nd, pair the arthritis with mouse have the function that adjunctive therapy
3rd, croton oil edema is tested with mouse
4th, ultraviolet erythema is tested on Guinea piggy
Bisabolol all has the effect of obvious anti-inflammatory, anti-inflammatory and anti-erythema in above all of experiment.
Enoxolone tristearin alcohol ester is that enoxolone and stearyl alcohol are formed by esterification, compared with enoxolone, by
The molecular structure of oil loving higher alkane has been imported in molecule, its dissolubility in grease is significantly improved, energy
Mixed with a variety of greases and higher alcohol, compatibility is good：Fusing point is low, and vapour pressure is high.Swash with antibacterial, antitumor and adrenal cortex
Plain sample effect, can be made into anti-inflammatory antiallergy preparation, for treating rheumatic arthritis, asthma, anaphylaxis and occupational dermatitis, eye
Ear-nose-throat department inflammation and ulcer etc..Enoxolone is classical anti-inflammatory drug, is applied in cosmetics and can adjust skin
Immunologic function, strengthen the resistance against diseases of skin, diminish inflammation, pre- hypo-allergenic, cleaning skin, at the same can also release cosmetics and its
Toxic side effect of its extraneous factor to skin.It can also effectively suppress the activation of tyrosinase, prevent the generation of melanin, have
White-skinned face function enoxolone Recent Progresses In The Development.
Enoxolone tristearin alcohol ester antiinflammatory action：Anderso and Tillman notices that enoxolone tristearin alcohol ester exists earliest
It is similar with hydrocortisone in structure, just it is used in various treating for skin disease, by many clinical tests, confirmed sweet
The anti-inflammatory validity of careless hypo acid tristearin alcohol ester.Thus start, vast medical field has carried out a series of pharmacological researches, finds such spread out
It is many in biology that all there is anti-inflammatory activity.Zakirov researchs are found：Nothing of the 3- amino -11- deoxy-glycyrrhetinic acids to all kinds of animals
Bacterium property arthritis shows obvious anti-inflammatory activity.Toyoshima etc. prepare 11- deoxy-glycyrrhetinic acids maleate and
Its salt, as antiinflammatory, also as antiulcer agent and immunomodulator, orally or topically treat, obtain good therapeutic effect.
Enoxolone tristearin alcohol ester antiulcer action：Nineteen forty-six Revers has reported the antiulcer action of radix glycyrrhizae earliest.From
This, Europe advances the research of this respect significantly, and throws oneself into and the experiment of new drug is prepared by enoxolone tristearin alcohol ester.Synthesis
Castraausil salt, and find its effect of healing to gastric ulcer.French Demande researchs in 1972
It was found that 3- acetyl group -18- enoxolones and its aluminium salt are used to treat duodenal ulcer, gastric ulcer, curative effect is obvious.In addition, 11-
Deoxy-glycyrrhetinic acid acid amides, 3- oxy-acetyl enoxolone acid amides etc. are also very noticeable to the therapeutic effect of canker.
The antitumor proliferative activity of enoxolone：The researchs such as Japanese Takizawa in 1985 are found:Enoxolone is to muroid
The hyperplasia of dermatoma has suppression to use.Nishino and Hoyoku etc. to the Enoxolone derivative of dependency structure grind extensively
Study carefully, it is found that 18- oleanane -12- alkene -3,23,28- triols have suppression as virus caused by the tumour more stronger than enoxolone
Anti-proliferative effect.
Phloretin is a kind of external new type natural skin-whitening agents for researching and developing out recently, be distributed mainly on apple,
The pericarp and root skin of the rich fruits such as pears.The excessive secretion of sebaceous glands can also be suppressed, secrete vigorous type acne for treating；Can suppression
Melanocyte activity processed, there is effect to various skin splash；Other function factors in formula can be promoted to absorb, be one
Plant safely and effectively transdermal penetration enhancer；The water of 4-5 times of weight itself can be absorbed, NMF can be doubled as in formula；It goes back simultaneously
With very strong anti-oxidation function, the free radical in skin can be removed.Compared with similar natural component ursin and kojic acid, on an equal basis
The phloretin of concentration is better than them to the inhibitory action of tyrosinase, and when it is compounded with ursin and/or kojic acid
When, inhibiting rate of the product to tyrosinase can be greatly improved, inhibiting rate is reached 100%.
Phloretin, ursin and kojic acid are compared as follows to tyrosinase inhibitory action：
Concentration when table one, phloretin, ursin and kojic acid maximum tyrosinase inhibition rate and 50% inhibiting rate
| Classification | Maximum tyrosinase inhibition rate concentration (ICmax) | 50% inhibiting rate concentration (IC50) |
| Phloretin | 0.3% | 0.05% |
| Ursin | 1.4% | 0.81% |
| Kojic acid | 0.24% | 0.038% |
The inhibiting rate of table two, the phloretin of various concentration, ursin and kojic acid to tyrosinase
The inhibiting rate of table three, phloretin and ursin compatibility to tyrosinase
| Concentration % | Inhibiting rate % |
| Phloretin 0.06%+ ursin 0.26% | 100.0 |
| Phloretin 0.12%+ ursin 0.19% | 100.0 |
| Phloretin 0.17%+ ursin 0.12% | 98.52 |
| Phloretin 0.23%+ ursin 0.06% | 89.1 |
The inhibiting rate of table four, phloretin and kojic acid compatibility to tyrosinase
| Concentration % | Inhibiting rate % |
| Phloretin 0.06%+ kojic acids 0.25% | 85.5 |
| Phloretin 0.12%+ kojic acids 0.18% | 100.0 |
| Phloretin 0.18%+ kojic acids 0.12% | 100.0 |
| Phloretin 0.24%+ kojic acids 0.06% | 98.6 |
Table five, quality standard
| Inspection project | Unit | Standard provides | Method |
| Outward appearance | Off-white color crystalline powder | Ocular estimate | |
| Moisture | % | ≤2.0 | Oven method |
| Fusing point | ℃ | 257-259℃ | Melting point apparatus method |
| Content | % | ≥98 | HPLC methods |
| Total number of bacteria | Individual/gram | ＜ 500 | Dilution-plate method |
| Content of beary metal | ppm | ＜ 20 | Absorption spectrometry |
The function of phloretin：
1st, new, efficient, safe skin U.S. agent.It is better than ursin to the inhibiting rate of tyrosinase, it is equal to kojic acid, but
There is no the side effect of kojic acid, be a kind of very safely and effectively freckle removing and whitening agent.
2nd, very strong moisture-keeping function, the moisture of 4-5 times of weight itself can be absorbed.
3rd, it is a kind of very safely and effectively transdermal penetration enhancer, can promotes absorbing for other function factors in being formulated,
It is set to have given play to the effect of more preferable.
4th, there is very strong anti-oxidation function, the free radical in skin can be removed.
5th, the excessive secretion of sebaceous glands can be suppressed, vigorous type acne are secreted in treatment.
Acetyl chitosamine, also known as N-Acetyl-D-glucosamine, natural N-Acetyl-D-glucosamine (oligosaccharides NAG) are shrimp and crab shells through going
Protein and after going mineral matter to handle, then be made with special natural ferment hydrolysis.Experiment finds there is increase skin hyaluronic acid
Containing content, slow down arthralgia, improve diabetes and hepatitis symptom and the effect of enhancement immunocompetence.NAG is a kind of efficient
Moisturizing ingredient.It reaches whitening effect by promoting the hydration function of skin.In addition, NAG, which also has, suppresses tyrosinase
The effect of activity, the melanin generation in melanocyte can be suppressed.In addition, NAG can also adjust corneocyte adhesion,
Promote cuticula to peel off, promote the metabolism of skin, skin is seemed healthy, pale, penetrating.
Liquaemin, liquaemin are mucopolysaccharide sulfuric acid ester anticoagulants.Liquaemin is by being extracted in the intestinal mucosa of pig or ox
CSSO3 sodium salt, belong to mucopolysaccharide material.With powerful negative electrical charge, have and strengthen antithrombin Ⅲ inactivation
The effect of serine protease, so as to prevent the formation of fibrin ferment, and have and prevent a variety of anticoagulations such as platelet aggregation.At present
Heparin is the maximum anticoagulation medicine of most effective in the world and quantity, is mainly used in cardiovascular and cerebrovascular disease and haemodialysis
Treatment, wherein, it is the only effective specific medicament in hemodialysis.Clinical practice and studies have shown that heparin are except tool
Have outside blood coagulation resisting function, it is also thin with other multiple biological activities and clinical application, including effect for reducing blood fat, anti-middle film smooth muscle
Born of the same parents (SMC) hyperplasia, promote the effect such as fibrinolysis.In addition, LMWHs is to enter one as raw material by heparin bulk drug
The medicine for the major class antithrombotic being processed into is walked, there is more extensive clinical medicine purposes, turns into treatment Acute Venous thrombus
With the choice drug of the disease such as acute coronary artery syndrome (angina pectoris, miocardial infarction).
Asiaticosid, asiaticosid are also known as Asiaticoside, faint yellow to fallow powder；It is odorless, bitter, slightly have
Draw moist.There is promotion Wound Healing.For treating wound, operation wound, burn, keloid and chorionitis.Asiaticoside
There is the function of enhancing reticuloendothelial system, excite capillary to regenerate, improve blood circulation, activate epithelial tissue, promote normal
Granulation tissue is formed, and accelerates wound repair.Experimental data shows that LPS can substantially induce the propagation of in vitro culture microglia
Discharged with inflammatory factor.Compared with LPS groups, microglia that asiaticosid is induced LPS propagation, which has, significantly inhibits effect,
And there is dose dependent, asiaticosid processing microglia 48h IC50 is 10.97nmol/L.Asiaticosid makes simultaneously
The release of microglia TNF-α and IL-6 significantly reduces (P ＜ 0.05)；Asiaticosid make the G2 phases cell of microglia with
Apoptosis rate increase, and reduce microglia TLR4 and NF- κ B expression.The small colloid that asiaticosid is stimulated LPS is thin
The generation of the propagation and inflammatory factor of born of the same parents is inhibited, and its mechanism of action may be with suppressing TLR-4 and NF- κ B expression, changing
Become the cell cycle and inducing cell apoptosis is relevant.
Troxerutin, different name：Hydroxyethyl rutin, troxerutin, vitamin P4, it is that rutin is extracted from sophora flower, then passes through
Semi-synthetic chromocor compound made of hydroxyethylation, have and suppress red blood cell and platelet aggregation effect, prevent thrombosis, together
When can increase the content of oxygen in blood, improve microcirculation, promote new vascular generation to promote Doppler flow mapping.Its Human Umbilical Vein Endothelial Cells has guarantor
Shield acts on, and can ease up medmain injury of blood vessel caused by kassinin kinin, increases the resistance of capillary, reduces capillary
Permeability, prevent because vasopermeability raise caused by oedema, and have resistance to radioactive injuries, anti-inflammatory,
The composition adds emulsifying agent, preservative, thickener and NMF and can be made into creme, emulsion, Essence, skin toner
Water and gel,
The emulsifying agent includes：Cetearyl glucoside, Phosphoric acid monohexadecyl ester potassium, hydrolecithin, glycerol stearate
One or more in ester (SE), Cremophor RH40 ester,
The preservative includes：It is Phenoxyethanol, methyl hydroxybenzoate, ethyl hydroxy benzoate, Nipasol, methylisothiazolinone, double
One or more in (methylol) imidazolidinyl urea, iodine propilolic alcohol butyl mephenesin Carbamate,
The thickener includes：Carbomer, xanthans, hydroxyethyl cellulose, carragheen, hydroxy-ethyl acrylate/acryloyl
One or more in dimethyltaurine sodium copolymer,
The NMF includes：One or more in glycerine, propane diols, butanediol, sorbierite, erythrite, xylitol.
Embodiment
The principle and feature of the present invention are described below in conjunction with specific embodiment, example is served only for explaining this hair
It is bright, it is not intended to limit the scope of the present invention.
Embodiment one
A kind of composition with anti-acne trace and suppression acne growth function, including component A and B component,
The component A includes the raw material of following parts by weight：Phytosterol 1g, bisabolol 1g and enoxolone tristearin alcohol ester
0.5g；
The B component includes following weight g raw material：Phloretin 1g, acetyl chitosamine 5g, liquaemin 1g, asiaticosid
1g and Troxerutin 2g；
Component A and B component weight ratio are 2.5：10.
Embodiment two
A kind of composition with anti-acne trace and suppression acne growth function, including component A and B component,
The component A includes the raw material of following parts by weight：Phytosterol 0.2g, bisabolol 0.8g and enoxolone are stearic
Alcohol ester 0.5g；
The B component includes following weight g raw material：Phloretin 1g, acetyl chitosamine 4g, liquaemin 0.5g, centella
Glycosides 1g and Troxerutin 2g；
Component A and B component weight ratio are 1.5：8.5.
Embodiment three
A kind of composition with anti-acne trace and suppression acne growth function, including component A and B component,
The component A includes the raw material of following parts by weight：Phytosterol 0.5g, bisabolol 0.5g and enoxolone are stearic
Alcohol ester 0.5g；
The B component includes the raw material of following parts by weight：Phloretin 0.5g, acetyl chitosamine 3g, liquaemin 0.5g, accumulated snow
Careless glycosides 0.5g and Troxerutin 1.5g；
Component A and B component weight ratio are 1.5:6.
Example IV
A kind of creme with anti-acne trace and suppression acne growth function, includes following component per 100g cremes：
The molten phase component of oil：
Water-soluble phase component：
Surplus adds to 100g with deionized water,
Wherein component A includes phytosterol 0.5g, bisabolol 1g, enoxolone tristearin alcohol ester 0.5g；B component includes root
Skin element 1g, acetyl chitosamine 3g, liquaemin 1g, asiaticosid 1g and Troxerutin 1g.
A kind of creme preparation method with anti-acne trace and suppression acne growth function is as follows：
Oil phase, aqueous phase are heated separately to 80 DEG C, two-phase mixtures uniformly several minutes of homogeneous afterwards, stirring cooling, 45 DEG C add
Essence, stir, 35 DEG C are made fine and smooth lotion；Lotion is weighed bottling.
Embodiment five
A kind of emulsion with anti-acne trace and suppression acne growth function, includes following component per 100g emulsions：
The molten phase component of oil：
Water-soluble phase component：
Surplus adds to 100g with deionized water,
Wherein component A includes phytosterol 0.5g, bisabolol 0.5g, enoxolone tristearin alcohol ester 0.5g；B component includes
Phloretin 0.5g, acetyl chitosamine 2g, liquaemin 0.3g, asiaticosid 0.2g and Troxerutin 1g.
A kind of preparation method with anti-acne trace and the emulsion for suppressing acne growth function is identical with example IV.
Embodiment six
A kind of Essence with anti-acne trace and suppression acne growth function, includes following component per 100g Essences：
The molten phase component of oil：
Water-soluble phase component：
Surplus adds to 100g with deionized water,
Wherein component A includes phytosterol 1.0g, bisabolol 1.0g and enoxolone tristearin alcohol ester 1.0g；B component bag
Include phloretin 1g, acetyl chitosamine 4g, liquaemin 1g, asiaticosid 1g and Troxerutin 2g.
A kind of preparation method with anti-acne trace and the Essence for suppressing acne growth function is as follows：
Oil phase, aqueous phase are heated separately to 80 DEG C, two-phase mixtures uniformly several minutes of homogeneous afterwards, stirring cooling, stirred,
35 DEG C are made fine and smooth lotion；Lotion is weighed bottling.
Embodiment seven
A kind of gel with anti-acne trace and suppression acne growth function, includes following component per 100g gels：
The molten phase component of oil：
Water-soluble phase component：
Surplus adds to 100g with deionized water,
Wherein component A includes phytosterol 0.3g, bisabolol 0.3g and enoxolone tristearin alcohol ester 0.2g；B component bag
Include phloretin 0.2g, acetyl chitosamine 1.5g, liquaemin 0.1g, asiaticosid 0.2g and Troxerutin 0.2g.
A kind of preparation method with anti-acne trace and the Essence for suppressing acne growth function is identical with embodiment six.
Embodiment eight
A kind of surfactant with anti-acne trace and suppression acne growth function, includes following component per 100g surfactant：
The molten phase component of oil：
Water-soluble phase component：
Surplus adds to 100g with deionized water,
Wherein component A includes phytosterol 0.1g, bisabolol 0.1g and enoxolone tristearin alcohol ester 0.1g；B component bag
Include phloretin 0.1g, acetyl chitosamine 3.0g, liquaemin 0.1g, asiaticosid 0.1g and Troxerutin 0.5g.
A kind of preparation method with anti-acne trace and the surfactant for suppressing acne growth function is identical with embodiment six.
Embodiment nine
A kind of facial mask with anti-acne trace and suppression acne growth function, every 100 parts by weight facial mask include following component：
The molten phase component of oil：
Water-soluble phase component：
Surplus adds to 100g with deionized water,
Wherein component A includes phytosterol 0.1g, bisabolol 0.1g and enoxolone tristearin alcohol ester 0.1g；B component bag
Include phloretin 0.1g, acetyl chitosamine 0.5g, liquaemin 0.05g and asiaticosid 0.1g.
A kind of preparation method with anti-acne trace and the facial mask for suppressing acne growth function is identical with embodiment six.
Both effectiveness test：
First, normal individual trial evaluation experimental
1st, experimental method
Embodiment one carries out normal individual trial evaluation.Patient 16 after acne is cured is chosen, the age, men and women was each at 18~25 years old
Half.Wherein IV degree of male suffer from again 3, IV degree of women suffer from 1 again.Check experiment is carried out respectively, and left side is right without using any product
Side uses this example sample, takes pictures and keeps on file before use, using two to three times after daily face cleaning, persistently tries out surrounding, using first week, the
After two weeks, the 3rd week and 4th week, the pockmark apparent condition of left face and right face is observed respectively, with using preceding photo pair after four weeks
Than, while observe the emerging acne generation situation of left and right face.
Area, surface of a wound flatness and newborn acne quantity are printed during use to sample colourity, color to evaluate, wherein most
High score is 5, minimum to be divided into 1.
2nd, experimental result
Evaluation table on probation is filled according to sensory evaluation.Half face experiment evaluation table on probation is collected, statistical result see the table below：
Normal individual trial evaluation result average value：
From upper table result, the result of the face test evaluation of human body half clearly can contrast this example sample and blank sample
The effect of product difference, colourity, color print area, surface of a wound flatness and newborn acne quantity improvement in terms of positive effect, show to contain
The present invention has anti-acne trace and suppresses the anti-acne trace frost of the cosmetic composition of acne systematic function, has good elimination red
Acne print, the light black acne print that subtracts, repair acne scar and suppress the function of the generation of new acne.
Wherein component A and B component ratio, which change to be tested, can also obtain good experimental result.
2nd, normal individual trial evaluation experimental
1st, experimental method
Embodiment two carries out normal individual trial evaluation.Patient 16 after acne is cured is chosen, the age, men and women was each at 18~25 years old
Half.Wherein IV degree of male suffer from again 3, IV degree of women suffer from 1 again.Check experiment is carried out respectively, and left side is right without using any product
Side uses this example sample, takes pictures and keeps on file before use, using two to three times after daily face cleaning, persistently tries out surrounding, using first week, the
After two weeks, the 3rd week and 4th week, the pockmark apparent condition of left face and right face is observed respectively, with using preceding photo pair after four weeks
Than, while observe the emerging acne generation situation of left and right face.
Area, surface of a wound flatness and newborn acne quantity are printed during use to sample colourity, color to evaluate, wherein most
High score is 5, minimum to be divided into 1.
2nd, experimental result
Evaluation table on probation is filled according to sensory evaluation.Half face experiment evaluation table on probation is collected, statistical result see the table below：
Normal individual trial evaluation result average value：
From upper table result, the result of the face test evaluation of human body half clearly can contrast this example sample and blank sample
The effect of product difference, colourity, color print area, surface of a wound flatness and newborn acne quantity improvement in terms of positive effect, show to contain
The present invention has anti-acne trace and suppresses the anti-acne trace frost of the cosmetic composition of acne systematic function, has good elimination red
Acne print, the light black acne print that subtracts, repair acne scar and suppress the function of the generation of new acne.
Wherein component A and B component ratio, which change to be tested, can also obtain good experimental result.
The foregoing is only presently preferred embodiments of the present invention, be not intended to limit the invention, it is all the present invention spirit and
Within principle, any modification, equivalent substitution and improvements made etc., it should be included in the scope of the protection.
Claims (10)
- With anti-acne trace and suppress the composition of acne growth function 1. a kind of, it is characterised in that including component A and B component,The component A includes the raw material of following parts by weight：0.1~1 part of phytosterol, 0.1~2 part of bisabolol and enoxolone Stearic 0.1~1 part of alcohol ester；The B component includes the raw material of following parts by weight：0.1~1 part of phloretin, 0.5~5 part of acetyl chitosamine, liquaemin 0.1~2 part of 0.05~1 part, 0.1~1 part of asiaticosid and Troxerutin；The component A and the B component weight ratio are 0.3~3：0.85~10.
- With anti-acne trace and suppress the composition of acne growth function 2. a kind of, it is characterised in that including component A and B component,The component A includes the raw material of following parts by weight：0.2~1 part of phytosterol, 0.1~1 part of bisabolol and enoxolone Stearic 0.1~0.5 part of alcohol ester；The B component includes the raw material of following parts by weight：0.1~1 part of phloretin, 0.5~4 part of acetyl chitosamine, liquaemin 0.1~20 part of 0.05~0.5 part, 0.1~1 part of asiaticosid and Troxerutin；The component A and the B component weight ratio are 0.4~2.5：0.85~8.5.
- A kind of 3. composition with anti-acne trace and suppression acne growth function according to claim 1, it is characterised in that Including component A and B component,The component A includes the raw material of following parts by weight：0.5 part of phytosterol, 0.5 part of bisabolol and enoxolone stearyl alcohol 0.5 part of ester；The B component includes the raw material of following parts by weight：0.5 part of phloretin, 3 parts of acetyl chitosamine, 0.5 part of liquaemin, accumulated snow 1.5 parts of 0.5 part of careless glycosides and Troxerutin；The component A and the B component weight ratio are 1.5:6.
- 4. the composition for having anti-acne trace described in a kind of any one of claims 1 to 3 and suppressing acne growth function is preparing skin Application on skin care product.
- 5. it is a kind of with anti-acne trace and suppress acne growth function creme, it is characterised in that every 100 parts by weight creme include with The lower molten phase component of oil and water-soluble phase component：The molten phase component of oil includes the material of following parts by weight：There is anti-acne trace and suppression described in any one of claims 1 to 3 2.0 parts of component A and 3 parts of cetearyl glucoside, Phosphoric acid monohexadecyl ester potassium 0.5 in the composition of acne growth function Part, 4 parts of tea leaf oil, 1.8 parts of cetostearyl alcohol, 0.1 part of Vitwas E and 1 part of dimethyl silicone polymer,The water-soluble phase component includes the material of following parts by weight：There is anti-acne trace and suppression described in any one of claims 1 to 3 7.0 parts of B component and 0.05 part of disodium ethylene diamine tetraacetate, 0.2 part of allantoin, glycerine in the composition of acne growth function 6 parts, 4 parts of butanediol, 0.3 part of Sodium Polyacrylate, 0.1 part of xanthans, 0.05 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol, oxybenzene 0.05 part of 0.2 part of methyl esters and essence,Surplus is supplied with deionized water.
- 6. it is a kind of with anti-acne trace and suppress acne growth function emulsion, it is characterised in that every 100 parts by weight emulsion include with The lower molten phase component of oil and water-soluble phase component：The molten phase component of oil：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 1.5 parts of component A and 1.5 parts of cetearyl glucoside, 0.3 part of Phosphoric acid monohexadecyl ester potassium, 2 parts of tea leaf oil, spermaceti it is hard 1 part of 0.8 part of lipidol, 0.1 part of Vitwas E and dimethyl silicone polymer,The water-soluble phase component：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 4.0 parts of B component and 0.05 part of disodium ethylene diamine tetraacetate, 0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, polypropylene Sour 0.2 part of sodium, 0.1 part of xanthans, 0.05 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol, 0.2 part of methyl hydroxybenzoate and essence 0.05 Part,Surplus is supplied with deionized water.
- A kind of 7. Essence with anti-acne trace and suppression acne growth function, it is characterised in that every 100 parts by weight Essence bag Include the molten phase component of following oil and water-soluble phase component：The molten phase component of oil：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 3.0 parts of component A and 0.5 part of hydrolecithin, 0.1 part of Phosphoric acid monohexadecyl ester potassium, 1 part of tea leaf oil, Vitwas E 0.1 part and 1 part of dimethyl silicone polymer,The water-soluble phase component：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 9.0 parts of B component and 0.05 part of disodium ethylene diamine tetraacetate, 0.2 part of allantoin, 8 parts of glycerine, 4 parts of butanediol, polypropylene 0.2 part of sour 0.5 part of sodium, 0.1 part of xanthans, 0.1 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,Surplus is supplied with deionized water.
- 8. it is a kind of with anti-acne trace and suppress acne growth function gel, it is characterised in that every 100 parts by weight gel include with The lower molten phase component of oil and water-soluble phase component：The molten phase component of oil：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 0.8 part of component A and 0.5 part of hydrolecithin, 0.1 part of Phosphoric acid monohexadecyl ester potassium, 1 part of tea leaf oil, Vitwas E 0.1 part and 0.5 part of dimethyl silicone polymer,The water-soluble phase component：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 2.2 parts of B component and 0.5 part of disodium ethylene diamine tetraacetate, 0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, polypropylene 0.2 part of sour 0.6 part of sodium, 0.05 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,Surplus is supplied with deionized water.
- A kind of 9. surfactant with anti-acne trace and suppression acne growth function, it is characterised in that every 100 parts by weight surfactant bag Include the molten phase component of following oil and water-soluble phase component：The molten phase component of oil：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 0.3 part of component A and 0.3 part of hydrolecithin, 0.05 part of the Vitwas E and dimethyl silicone polymer 0.5 of ring penta Part,The water-soluble phase component：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 3.8 parts of B component and 0.05 part of disodium ethylene diamine tetraacetate, 0.1 part of allantoin, 5 parts of glycerine, 4 parts of butanediol, polypropylene 0.2 part of sour 0.2 part of sodium, 0.2 part of xanthans, 0.05 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,Surplus is supplied with deionized water.
- 10. a kind of facial mask with anti-acne trace and suppression acne growth function, it is characterised in that every 100 parts by weight facial mask includes The following molten phase component of oil and water-soluble phase component：The molten phase component of oil：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 0.4 part of component A and 3 parts of cetearyl glucoside, 0.5 part of Phosphoric acid monohexadecyl ester potassium, 4 parts of tea leaf oil, cetearyl alcohol 1 part of 1.8 parts of alcohol, 0.1 part of Vitwas E and dimethyl silicone polymer,The water-soluble phase component：There is anti-acne trace described in any one of claims 1 to 3 and suppress the composition of acne growth function In 0.85 part of B component and 0.05 part of disodium ethylene diamine tetraacetate, 0.2 part of allantoin, 6 parts of glycerine, 4 parts of butanediol, poly- third 0.2 part of 0.3 part of olefin(e) acid sodium, 0.3 part of hydroxyethyl cellulose, 0.05 part of Sodium Hyaluronate, 0.4 part of Phenoxyethanol and methyl hydroxybenzoate,Surplus is supplied with deionized water.
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510873881.2A CN105380830B (en) | 2015-12-02 | 2015-12-02 | A kind of composition and its application with anti-acne trace and suppression acne systematic function |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN201510873881.2A CN105380830B (en) | 2015-12-02 | 2015-12-02 | A kind of composition and its application with anti-acne trace and suppression acne systematic function |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CN105380830A CN105380830A (en) | 2016-03-09 |
| CN105380830B true CN105380830B (en) | 2017-11-21 |
Family
ID=55414013
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CN201510873881.2A Active CN105380830B (en) | 2015-12-02 | 2015-12-02 | A kind of composition and its application with anti-acne trace and suppression acne systematic function |
Country Status (1)
| Country | Link |
|---|---|
| CN (1) | CN105380830B (en) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN107184410A (en) * | 2017-04-28 | 2017-09-22 | 广州瑞誉化工科技有限公司 | A kind of skin cream with steroid dependent dermatitis repair function |
| CN108175727A (en) * | 2017-12-28 | 2018-06-19 | 广州蜜妆生物科技有限公司 | A kind of anti-acne print Face-protecting mask patch and preparation method thereof |
| CN109568231A (en) * | 2018-12-30 | 2019-04-05 | 广州瑞誉化工科技有限公司 | It is a kind of can Red blood streak dispelling skin composition and its preparation method and application |
| CN110063925A (en) * | 2019-03-19 | 2019-07-30 | 广东医科大学 | A kind of acne-removing composition and preparation method thereof |
| CN110302087B (en) * | 2019-08-16 | 2022-07-19 | 广州立白企业集团有限公司 | Repairing composition, application and skin care composition containing repairing composition |
| CN114028271B (en) * | 2021-11-26 | 2022-11-08 | 西安德诺海思医疗科技有限公司 | Oil-control acne-removing composition and preparation method thereof |
| CN116869886B (en) * | 2023-07-27 | 2024-04-02 | 广州市精锐生物研究有限公司 | Acne-removing composition, and preparation method and application thereof |
Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931269A (en) * | 2006-10-13 | 2007-03-21 | 深圳市生物谷科技有限公司 | Rutin containing medicine composition |
| CN103976907A (en) * | 2014-05-29 | 2014-08-13 | 暨南大学 | Cosmetic comprising composition with slow anti-allergic action as well as preparation method and application thereof |
| CN104997711A (en) * | 2015-07-20 | 2015-10-28 | 陈巨根 | Scar dispelling and speckle removing essential oil |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20030082116A1 (en) * | 2001-09-28 | 2003-05-01 | Closure Medical Corporation | Adhesive compositions containing dual function stabilizers and active agents |
-
2015
- 2015-12-02 CN CN201510873881.2A patent/CN105380830B/en active Active
Patent Citations (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN1931269A (en) * | 2006-10-13 | 2007-03-21 | 深圳市生物谷科技有限公司 | Rutin containing medicine composition |
| CN103976907A (en) * | 2014-05-29 | 2014-08-13 | 暨南大学 | Cosmetic comprising composition with slow anti-allergic action as well as preparation method and application thereof |
| CN104997711A (en) * | 2015-07-20 | 2015-10-28 | 陈巨根 | Scar dispelling and speckle removing essential oil |
Also Published As
| Publication number | Publication date |
|---|---|
| CN105380830A (en) | 2016-03-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN105380830B (en) | A kind of composition and its application with anti-acne trace and suppression acne systematic function | |
| CN105434195B (en) | A kind of composition and its application with anti-acne and suppression pockmark systematic function | |
| KR101373636B1 (en) | Composition for improving condition of skin and scalp containing fermented extracts of herb mixture | |
| EP1538927B1 (en) | Fruit and/or vegetable derived composition | |
| CN105395467B (en) | A kind of Chinese medicine composition, skin beautifying cosmetic and its application | |
| KR102033089B1 (en) | Compositions for decreasing sebum, skin desquamation and skin suppression | |
| CN105213284A (en) | A kind of anti-acne moisturiser and preparation method thereof | |
| KR101387308B1 (en) | Skin whitening composition by using of dendropanax morbifera ferment extract | |
| KR101015702B1 (en) | Compositions comprising Seaweeds extract for improving and alleviating inflammation and irritation of skin | |
| JP2010132629A (en) | External composition for skin | |
| CN102274141B (en) | Herba selaginellae revival moisturizing cream and preparation method thereof | |
| CN105997827A (en) | Compound camellia oil moisturizer and preparation method thereof | |
| CN105310933A (en) | Formula of active ingredients of anti-aging beauty mask | |
| KR101817514B1 (en) | New use of hesperetin | |
| KR100769302B1 (en) | Skin topical composition containing herbal extract for treating and improving scar pruritus | |
| CN105125467A (en) | Emulsion removing red blood and preparing method of emulsion | |
| CN115429738B (en) | Acne-removing, repairing and reviving essence and preparation method thereof | |
| KR100372360B1 (en) | Cosmetic compositions containing garlic and Acanthopanax extracts | |
| CN112266825A (en) | Compound essential oil, preparation method thereof and application of compound essential oil in whitening and anti-wrinkle cosmetics | |
| JP2004345959A (en) | Melanogenesis promoter and melanogenesis-promoting composition | |
| CN108403485A (en) | Natural herb sunscreen | |
| KR101501538B1 (en) | Composition for External Application to the Skin Using an Extract of Seeds of Opuntia ficus-indica var. saboten | |
| KR20160036834A (en) | Skin external application composition comprising complex fermented extract of crude drug ingredients | |
| CN110151657B (en) | Acne removing gel containing sedum sarmentosum extract and preparation method thereof | |
| Adom et al. | The chemical constituents, anti-inflammatory, anti-oxidant, and ethnomedicinal properties of aloe barbadensis |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| C06 | Publication | ||
| PB01 | Publication | ||
| C10 | Entry into substantive examination | ||
| SE01 | Entry into force of request for substantive examination | ||
| GR01 | Patent grant | ||
| GR01 | Patent grant | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20201224 Address after: No.6, 1st floor, unit 107, building 1, No.1, middle section of Tianfu Avenue, Chengdu high tech Zone, Chengdu, Sichuan 610213 Patentee after: Strawberry jam Technology Chengdu Co.,Ltd. Address before: 510000 706, building 6, Hongtai wisdom Valley, 21 Sicheng Road, Tianhe District, Guangzhou City, Guangdong Province Patentee before: GUANGZHOU DOUHU BIOTECHNOLOGY Co.,Ltd. Patentee before: Yin Chuanjiang Patentee before: Yang Min |
|
| TR01 | Transfer of patent right | ||
| TR01 | Transfer of patent right |
Effective date of registration: 20240517 Address after: Room 323, No.1 Huaxu Street, Tianhe District, Guangzhou City, Guangdong Province, 510630 Patentee after: Amoer (Guangzhou) Biotechnology Co.,Ltd. Country or region after: China Address before: No.6, 1st floor, unit 107, building 1, No.1, middle section of Tianfu Avenue, Chengdu high tech Zone, Chengdu, Sichuan 610213 Patentee before: Strawberry jam Technology Chengdu Co.,Ltd. Country or region before: China |